Kinnevik AB (publ) - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.

Quarter-by-quarter ownership
Kinnevik AB (publ) ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$79,603,360
+2.4%
10,405,6680.0%100.00%0.0%
Q2 2023$77,730,340
+52.3%
10,405,668
+36.0%
100.00%
+46.0%
Q1 2023$51,045,917
-13.5%
7,653,0610.0%68.47%
+105.7%
Q4 2022$59,005,1007,653,06133.28%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 5,977,631$42,800,000100.00%
Two Sigma Ventures, LP 1,806,800$12,937,00074.73%
DCVC Opportunity Fund II GP, LLC 3,951,141$28,290,00031.54%
MV Management XI, L.L.C. 1,971,908$14,119,0009.80%
Data Collective IV GP, LLC 5,941,120$42,538,0009.03%
ArchPoint Investors 1,267,430$9,075,0003.13%
MIC Capital Management UK LLP 1,388,889$9,944,0001.94%
HARVARD MANAGEMENT CO INC 1,509,254$10,806,0001.09%
Samsara BioCapital, LLC 539,236$3,861,0000.97%
Pinz Capital Management, LP 142,168$1,018,0000.64%
View complete list of RECURSION PHARMACEUTICALS IN shareholders